gatifloxacin has been researched along with Infections, Respiratory in 22 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this community-based safety surveillance study, the advanced-generation fluoroquinolone gatifloxacin was administered empirically to 15625 adults with community-acquired respiratory tract infections (RTIs), including 1562 clinically evaluable patients with community-acquired pneumonia (CAP) and 2391 with acute exacerbations of chronic bronchitis (AECB)." | 9.10 | Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin. ( Andriole, VT; Jones, RN; Nicholson, SC; Webb, CD; Wilson, WR, 2002) |
| " The serum concentration of GFLX was measured for each patient, and population and pharmacokinetic (PPK) analysis was performed, using the Bayesian method, to calculate the AUC and maximum drug concentration (Cmax)." | 6.73 | Evaluation of clinical dosage of gatifloxacin for respiratory tract infections in elderly patients based on pharmacokinetics/pharmacodynamics (PK/PD). ( Hara, H; Kamao, T; Kawanishi, M; Kimura, M; Kishimoto, M; Matsushima, T; Miyashita, N; Moriya, O; Nakamura, J; Niki, Y; Oka, M; Okimoto, N; Tanimukai, T; Uno, M; Watanabe, M; Yoneyama, H; Yoshida, K, 2008) |
| "This study showed that the treatment of respiratory tract infections with gatifloxacin was safe and efficient and had a low incidence of adverse events." | 6.70 | Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin. ( Medeiros, EA, 2002) |
| "Gatifloxacin 400 mg was administered once daily for seven to 14 days." | 6.70 | Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly. ( Gothelf, S; High, KP; Nicholson, SC; Webb, CD, 2002) |
| "In this community-based safety surveillance study, the advanced-generation fluoroquinolone gatifloxacin was administered empirically to 15625 adults with community-acquired respiratory tract infections (RTIs), including 1562 clinically evaluable patients with community-acquired pneumonia (CAP) and 2391 with acute exacerbations of chronic bronchitis (AECB)." | 5.10 | Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin. ( Andriole, VT; Jones, RN; Nicholson, SC; Webb, CD; Wilson, WR, 2002) |
| "We investigated the in vitro activity of AR-709, a novel diaminopyrimidine antibiotic currently in development for treatment of community-acquired upper and lower respiratory tract infections, against 151 Streptococcus pneumoniae strains from various European countries." | 3.74 | In vitro activity of AR-709 against Streptococcus pneumoniae. ( Jansen, WT; Milatovic, D; Verel, A; Verhoef, J, 2008) |
| " The serum concentration of GFLX was measured for each patient, and population and pharmacokinetic (PPK) analysis was performed, using the Bayesian method, to calculate the AUC and maximum drug concentration (Cmax)." | 2.73 | Evaluation of clinical dosage of gatifloxacin for respiratory tract infections in elderly patients based on pharmacokinetics/pharmacodynamics (PK/PD). ( Hara, H; Kamao, T; Kawanishi, M; Kimura, M; Kishimoto, M; Matsushima, T; Miyashita, N; Moriya, O; Nakamura, J; Niki, Y; Oka, M; Okimoto, N; Tanimukai, T; Uno, M; Watanabe, M; Yoneyama, H; Yoshida, K, 2008) |
| "This study showed that the treatment of respiratory tract infections with gatifloxacin was safe and efficient and had a low incidence of adverse events." | 2.70 | Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin. ( Medeiros, EA, 2002) |
| "Gatifloxacin 400 mg was administered once daily for seven to 14 days." | 2.70 | Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly. ( Gothelf, S; High, KP; Nicholson, SC; Webb, CD, 2002) |
| " After an oral administration in humans, gatifloxacin is well absorbed and distributed, and the majority is excreted in the urine as the unchanged form." | 2.42 | [Antibacterial property and clinical effect of gatifloxacin, a novel quinolone antibacterial agent]. ( Hosaka, M, 2003) |
| "Gatifloxacin is a new 8-methoxy-fluoroquinoline antimicrobial agent." | 2.41 | Gatifloxacin: a new fluoroquinolone. ( Blondeau, JM, 2000) |
| "Gatifloxacin was the most active against P." | 1.32 | Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections. ( Daschner, F; Schmidt-Eisenlohr, E; Wenzler, S, 2004) |
| "Gatifloxacin was highly active against all three species." | 1.31 | In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-199 ( Bell, JM; Jones, RN; Pfaller, MA; Turnidge, JD, 2002) |
| "Gatifloxacin was active against streptococci, Escherichia coli, Klebsiella pneumoniae, Moraxella catarrhalis, Haemophilus influenzae and Neisseria gonorrhoeae, with MIC(90)s of | 1.31 | In vitro antimicrobial activity of gatifloxacin against 873 clinical isolates from respiratory tract, urinary tract and surgical infections during 1997-1998 in Japan. ( Hosaka, M; Manda, H; Takei, M; Tsurumaki, Y, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 19 (86.36) | 29.6817 |
| 2010's | 1 (4.55) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Jansen, WT | 1 |
| Verel, A | 1 |
| Verhoef, J | 1 |
| Milatovic, D | 1 |
| Bhawsar, S | 1 |
| Joshi, S | 1 |
| Deshpande, P | 1 |
| Yeole, R | 1 |
| Bhagwat, S | 1 |
| Patel, M | 1 |
| Gifford, J | 1 |
| Vaeth, E | 1 |
| Richards, K | 1 |
| Siddiqui, T | 1 |
| Gill, C | 1 |
| Wilson, L | 1 |
| DeLisle, S | 1 |
| Niki, Y | 1 |
| Yoshida, K | 1 |
| Miyashita, N | 1 |
| Oka, M | 1 |
| Hara, H | 1 |
| Kishimoto, M | 1 |
| Okimoto, N | 1 |
| Kawanishi, M | 1 |
| Uno, M | 1 |
| Kamao, T | 1 |
| Yoneyama, H | 1 |
| Nakamura, J | 1 |
| Kimura, M | 1 |
| Watanabe, M | 1 |
| Tanimukai, T | 1 |
| Moriya, O | 1 |
| Matsushima, T | 2 |
| Bell, JM | 1 |
| Turnidge, JD | 1 |
| Pfaller, MA | 2 |
| Jones, RN | 3 |
| Kohno, S | 1 |
| Watanabe, A | 1 |
| Medeiros, EA | 1 |
| Nicholson, SC | 2 |
| Webb, CD | 2 |
| Andriole, VT | 1 |
| Wilson, WR | 1 |
| High, KP | 1 |
| Gothelf, S | 1 |
| Matsuzaki, K | 1 |
| Watabe, E | 1 |
| Yoshimori, K | 1 |
| Shikano, M | 1 |
| Sato, Y | 1 |
| Hasegawa, M | 1 |
| Kobayashi, I | 1 |
| Stein, GE | 1 |
| Schooley, S | 1 |
| Tyrrell, KL | 1 |
| Citron, DM | 1 |
| Goldstein, EJ | 1 |
| Hosaka, M | 2 |
| Sethi, S | 1 |
| Wenzler, S | 1 |
| Schmidt-Eisenlohr, E | 1 |
| Daschner, F | 1 |
| Hoepelman, I | 1 |
| Hermsen, ED | 1 |
| Hovde, LB | 1 |
| Konstantinides, GN | 1 |
| Rotschafer, JC | 1 |
| Jain, S | 1 |
| Agarwal, J | 1 |
| Laskar, S | 1 |
| Gupta, T | 1 |
| Shrivastava, S | 1 |
| Sato, A | 1 |
| Kitazawa, H | 1 |
| Chida, K | 1 |
| Hayakawa, H | 1 |
| Iwata, M | 1 |
| Tsurumaki, Y | 1 |
| Manda, H | 1 |
| Takei, M | 1 |
| Smayevsky, J | 1 |
| Lopez, H | 1 |
| Di Chiara, M | 1 |
| Scarano, S | 1 |
| Lanza, A | 1 |
| Vilches, V | 1 |
| Stepanik, D | 1 |
| Bantar, C | 1 |
| Sucari, A | 1 |
| Blondeau, JM | 1 |
4 reviews available for gatifloxacin and Infections, Respiratory
| Article | Year |
|---|---|
[Antibacterial property and clinical effect of gatifloxacin, a novel quinolone antibacterial agent].
Topics: Animals; Anti-Infective Agents; Bacteria; Clinical Trials as Topic; DNA Topoisomerase IV; Drug Resis | 2003 |
Gatifloxacin in community-acquired respiratory tract infection.
Topics: Anti-Bacterial Agents; Biological Availability; Community-Acquired Infections; Fluoroquinolones; Gat | 2003 |
[New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gr | 2004 |
Gatifloxacin: a new fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Clinical Trials as Topic; Fluoroquinolones; Gatifloxacin; | 2000 |
5 trials available for gatifloxacin and Infections, Respiratory
| Article | Year |
|---|---|
Evaluation of clinical dosage of gatifloxacin for respiratory tract infections in elderly patients based on pharmacokinetics/pharmacodynamics (PK/PD).
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Female; Fluoroquin | 2008 |
Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin.
Topics: Adult; Aged; Anti-Infective Agents; Central Nervous System Diseases; Community-Acquired Infections; | 2002 |
Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Community-Acquired Infections; Drug Resis | 2002 |
Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin.
Topics: Administration, Oral; Anti-Infective Agents; Community-Acquired Infections; Dose-Response Relationsh | 2002 |
Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anti-Infective Agents; Community-Acquire | 2002 |
13 other studies available for gatifloxacin and Infections, Respiratory
| Article | Year |
|---|---|
In vitro activity of AR-709 against Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Europe; | 2008 |
WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Fluoroquinolones; Humans; Microbial Sensiti | 2022 |
Decision support during electronic prescription to stem antibiotic overuse for acute respiratory infections: a long-term, quasi-experimental study.
Topics: Anti-Bacterial Agents; Azithromycin; Decision Support Systems, Clinical; Electronic Prescribing; Flu | 2017 |
In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-199
Topics: Anti-Infective Agents; Asia; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Haemophilus | 2002 |
[The role of respiratory quinolone in treatment of respiratory tract infections: focusing on gatifloxacin].
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Fluoroquinolones; Gatifloxacin; Humans; Respiratory Tr | 2002 |
[Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Cefdinir; Cephalosporins; Ciprof | 2002 |
Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Aza Compounds; Bacteria, Aerobic; Bacteria, Anaerobi | 2003 |
Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
Topics: Abdominal Injuries; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria, Aerobic; Fluoroqui | 2004 |
Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Ha | 2005 |
Radiation recall dermatitis with gatifloxacin: a review of literature.
Topics: Anti-Infective Agents; Carcinoma, Squamous Cell; Dose-Response Relationship, Radiation; Drug Eruptio | 2008 |
Study of the effects of AM-1155 in a rat chronic respiratory tract infection model with Pseudomonas aeruginosa.
Topics: Animals; Anti-Infective Agents; Chronic Disease; Fluoroquinolones; Gatifloxacin; Immunoglobulin A; L | 1995 |
In vitro antimicrobial activity of gatifloxacin against 873 clinical isolates from respiratory tract, urinary tract and surgical infections during 1997-1998 in Japan.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Fluoroquinolones; Gatifloxacin; Humans; Japa | 2000 |
Activity of gatifloxacin compared to those of seven agents against bacteria recovered from outpatients with respiratory tract infection.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Drug Resistance, Microbial; Fluoroquin | 2000 |